🏛️ Verified NIH Record • Updated 2026-02-09
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) (NCT05396885)
A Phase II Study of CART-ddBCMA for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Kite, A Gilead Company
🩺 Plain-English Summary (8th-Grade Level)
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Cancer Transplant Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- HonorHealth Cancer Transplant Institute — Scottsdale, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Colorado Blood Cancer Institute — Denver, Colorado
- Moffitt Cancer Center — Tampa, Florida
- Northside Hospital — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
- Levine Cancer Institute — Charlotte, North Carolina
- Oregon Health & Science University (OHSU) — Portland, Oregon
- University of Texas Southwestern Medical Center — Dallas, Texas
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
- University of Wisconsin Clinical Science Center — Madison, Wisconsin
- Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.